levocetirizine dihydrochloride - Profile

What are the generic sources for levocetirizine dihydrochloride and what is the scope of patent protection?

Levocetirizine dihydrochloride is the generic ingredient in four branded drugs marketed by Apotex, Chartwell Molecular, Padagis Us, Taro, Hetero Labs Ltd Iii, Chattem Sanofi, Dr Reddys, Dr Reddys Labs Ltd, Glenmark Pharms Ltd, Granules, Ipca Labs Ltd, Macleods Pharms Ltd, Micro Labs Ltd India, Perrigo R And D, Sankalp Lifecare, Sciegen Pharms, Sun Pharm, Sun Pharm Inds Ltd, Synthon Bv, Teva Pharms, and Us Antibiotics, and is included in twenty-eight NDAs. There is one patent protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Levocetirizine dihydrochloride has thirty patent family members in twenty-four countries.

There is one tentative approval for this compound.

Summary for levocetirizine dihydrochloride

International Patents:	30
US Patents:	1
Tradenames:	4
Applicants:	21
NDAs:	28
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for levocetirizine dihydrochloride

Generic filers with tentative approvals for LEVOCETIRIZINE DIHYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		2.5MG/5ML	SOLUTION;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for LEVOCETIRIZINE DIHYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XYZAL	Oral Solution	levocetirizine dihydrochloride	0.5 mg/mL	022157	1	2009-01-14
XYZAL	Tablets	levocetirizine dihydrochloride	5 mg	022064	1	2007-12-17

US Patents and Regulatory Information for levocetirizine dihydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apotex	LEVOCETIRIZINE DIHYDROCHLORIDE	levocetirizine dihydrochloride	SOLUTION;ORAL	202915-001	Aug 21, 2014		DISCN	No	No
Chartwell Molecular	LEVOCETIRIZINE DIHYDROCHLORIDE	levocetirizine dihydrochloride	SOLUTION;ORAL	204599-001	May 15, 2017	AA	RX	No	No
Padagis Us	LEVOCETIRIZINE DIHYDROCHLORIDE	levocetirizine dihydrochloride	SOLUTION;ORAL	091263-001	Nov 7, 2011	AA	RX	No	Yes
Taro	LEVOCETIRIZINE DIHYDROCHLORIDE	levocetirizine dihydrochloride	SOLUTION;ORAL	202673-001	Jul 26, 2013		DISCN	No	No
Hetero Labs Ltd Iii	LEVOCETIRIZINE HYDROCHLORIDE	levocetirizine dihydrochloride	SOLUTION;ORAL	210914-001	Apr 1, 2019	AA	RX	No	No
Chattem Sanofi	XYZAL	levocetirizine dihydrochloride	SOLUTION;ORAL	022157-001	Jan 28, 2008		DISCN	Yes	No

Expired US Patents for levocetirizine dihydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chattem Sanofi	XYZAL	levocetirizine dihydrochloride	TABLET;ORAL	022064-001	May 25, 2007

International Patents for levocetirizine dihydrochloride

Country	Patent Number	Title	Estimated Expiration
New Zealand	552182	Pharmaceutical composition of piperazine derivatives
Taiwan	200605892	Pharmaceutical composition of piperazine derivatives
Cyprus	1109670
Norway	337768
South Korea	20070043841	PHARMACEUTICAL COMPOSITION OF PIPERAZINE DERIVATIVES
Japan	2008505949

Supplementary Protection Certificates for levocetirizine dihydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0058146	2001C/045	Belgium		PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
0663828	C300085	Netherlands		PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103

Levocetirizine Dihydrochloride: Investment Scenario and Fundamentals Analysis

Last updated: February 20, 2026

What Is the Market Profile for Levocetirizine Dihydrochloride?

Levocetirizine dihydrochloride is an antihistamine used primarily to treat allergic rhinitis and chronic idiopathic urticaria. It is the active enantiomer of cetirizine, offering increased potency and fewer sedative effects. The compound is marketed across various geographies, including North America, Europe, and Asia. The drug’s therapeutic indications and safety profile support its steady demand growth.

Market estimates project a compound annual growth rate (CAGR) of approximately 6-8% for the antihistamine segment from 2022 to 2027, driven primarily by increasing allergy prevalence, expanding aging populations, and rising awareness of allergy treatments. Existing patent protections for several branded formulations expire around 2023-2025, creating generic entry opportunities.

How Is the Revenue and Cost Structure Organized?

Revenue Drivers

• Sale of branded and generic formulations.
• Contract manufacturing and licensing agreements.
• Geographic expansion, particularly into emerging markets.

Cost Components

• Active pharmaceutical ingredient (API) synthesis costs.
• Development, clinical testing, and regulatory compliance expenses.
• Manufacturing costs, including quality control and compliance with Good Manufacturing Practices (GMP).
• Marketing and distribution expenses.

Profit Margins

Generic manufacturers can achieve gross margins of 50-70% depending on scale and patent status. Branded formulations typically enjoy higher margins but face patent challenges and pricing pressures.

What Are the Key Regulatory Considerations?

• Patent expiration timelines vary by region; patent cliffs are most imminent in North America and Europe.
• Regulatory approval processes for generics involve demonstrating bioequivalence, which typically takes 1-2 years.
• Post-approval, maintaining compliance with quality standards incurs ongoing costs.

Who Are the Major Players?

Company	Market Share	Key Products	Patent Status	Regulatory Approvals
UCB	~40% in Europe	Xyz branded formulations	Patent until 2025	Approved in major markets
Sandoz	As a generic producer	Generic levocetirizine	Patent expired in North America	Approved widely
Teva	Significant generic portfolio	Generic levocetirizine	Patent expired 2021	Approved globally

Investment Risks and Opportunities

Risks

• Patent expiries leading to increased generic competition.
• Price erosion driven by market saturation.
• Regulatory delays in emerging markets.
• Manufacturing disruptions affecting supply.

Opportunities

• Entry into emerging markets with accelerating allergy treatment adoption.
• Development of combination therapies or new formulations.
• Licensing deals for biosimilar or improved versions.
• Strategic acquisition of rights to older formulations nearing patent expiry.

Financial and Market Entry Considerations

• Capital expenditure requirements for manufacturing scale-up: USD 50–200 million depending on capacity.
• Payback period for generic entry: 2–3 years post-launch.
• Market penetration efforts and reimbursement landscapes influence profitability.
• Competitive landscape shifts as patent protections lapse.

Key Takeaways

Levocetirizine dihydrochloride remains a stable, growing market due to macro factors such as rising allergy prevalence. The upcoming patent expiries create opportunities for generic players but increase competitive pressures. Cost-efficient manufacturing and strategic geographic expansion are essential for profitability. Regulatory pathways are streamlined for generics but require significant due diligence.

FAQs

1. When do primary patents for branded levocetirizine expire?
Most patents are expected to expire between 2023 and 2025, enabling generic competition.

2. What are potential barriers to market entry for generics?
Regulatory approval delays, patent litigations, and manufacturing quality standards.

3. How does the global allergy market influence demand for levocetirizine?
Growing allergy prevalence, especially in urban regions, sustains consistent demand.

4. What competitive strategies are effective in this segment?
Rapid regulatory approval, cost-effective manufacturing, and strategic alliances with distributors.

5. Which emerging markets offer the greatest growth potential?
India, China, and Southeast Asian nations experience rising allergy incidences and evolving reimbursement landscapes.

---

References

1. MarketResearch.com. (2022). Anti-histamines Market Forecast to 2027.
2. U.S. Food and Drug Administration. (2022). Drug Approvals and Patent Data.
3. IMS Health (IQVIA). (2022). Global Prescription Drug Sales Data.
4. European Medicines Agency. (2022). Regulatory Pathways for Generics.
5. Sandoz. (2022). Annual Report on Generic Market Penetration.